Incyte

RIGOROUS SCIENCE, exacting performance metrics and a clear focus on patients accurately characterize Incyte’s approach to drug discovery and development.

INCYTE EMPLOYEES
all share the same goal: to have a direct impact on bringing new drugs to market that can improve patients' lives.

INCYTE

Learn More

is a biopharmaceutical company focused on discovering, developing and
commercializing proprietary small molecule drugs for oncology
and inflammation.

News

Incyte Reports 2012 First-Quarter Financial Results; Updates Shareholders on Commercial Activity and Key Clinical Programs

View press release

Incyte Announces EU Regulatory Milestone for Ruxolitinib

View press release

Phase III studies of Jakafi™ (ruxolitinib) published in The New England Journal of Medicine Demonstrate Significant Clinical Benefit for Patients with Myelofibrosis

View press release

Jakafi™

Press Releases
Prescribing Information
www.jakafi.com

IncyteCARES

Connecting to Access, Reimbursement, Education and Support
To learn more, click here

Secondary links

Primary links

Search

Secondary menu